← All stocks

Foghorn Therapeutics Inc.

FHTX Net buying

CIK 0001822462 #3226 in the set updated 21 Sep 2026

Bought (120 mo)

$4.89M

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$3.42M

$190.00K on a plan · $3.16M straight out of an exercise

Sold at will

$72.13K

1 of 8 sales

Net

+$1.47M

+$4.82M against sales at will

By person

11 insiders · 21 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Agresta Samuel

Chief Medical Officer

—

$2.57M (1) scheduled

−$2.57M

0.0000%

$0.00

—

Abu Dhabi Investment Authority

Former 10% Owner

$2.40M (1)

—

+$2.40M

1,231,081

2.07%

$12.52M

—

Flagship Ventures Fund V General Partner LLC entity

10% owner

$2.40M (3)

—

+$2.40M

1,851,801

3.12%

$18.83M

—

Costa Carlos

Chief People Officer

—

$591.16K (5) scheduled

−$591.16K

0.0000%

$0.00

—

Bellon Steven F.

Chief Scientific Officer

—

$190.00K (1) scheduled

−$190.00K

101,957

0.1717%

$1.04M

−11.9%

DECICCO CARL

Chief Scientific Officer

$88.00K (1)

—

+$88.00K

362,707

0.6108%

$3.69M

+43.4%

Cavalie Fanny

Chief Strategy/Bus Ops Officer

—

$72.13K (1)

−$72.13K

75,992

0.1280%

$772.84K

−12.6%

GOTTSCHALK ADRIAN

Chief Executive Officer

—

296,137

0.4987%

$3.01M

+42.4%

KADOCH CIGALL

Director

—

295,000

0.4968%

$3.00M

−53.1%

Reine Allan

Chief Financial Officer

—

53,784

0.0906%

$546.98K

+100.0%

GILL SIMBA

Director

—

34,061

0.0574%

$346.40K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Cavalie Fanny

11 Mar 2024

Chief Strategy/Bus Ops Officer

Sell

11,000

$6.56

$72.13K

Show all 21 transactions →

What was left out

Form 4 filings counted 125

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 4

Sales on a Rule 10b5-1 plan 1

Sales straight out of an exercise 6

Sales at will 1

Transactions with no price 0

Shares from compensation/vesting 17,233,848

History held since 28 Oct 2020